-$0.67 EPS Expected for Sarepta Therapeutics Inc (SRPT) This Quarter

Analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to announce earnings per share (EPS) of ($0.67) for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have issued estimates for Sarepta Therapeutics’ earnings, with estimates ranging from ($1.03) to ($0.32). Sarepta Therapeutics posted earnings per share of ($0.37) during the same quarter last year, which would indicate a negative year over year growth rate of 81.1%. The firm is expected to report its next quarterly earnings report on Thursday, March 7th.

On average, analysts expect that Sarepta Therapeutics will report full year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.30) to ($1.61). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.89) per share, with EPS estimates ranging from ($2.96) to ($0.45). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.29). Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 23.67%. The company had revenue of $78.49 million for the quarter, compared to analysts’ expectations of $78.84 million.

A number of brokerages have issued reports on SRPT. Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 21st. Cantor Fitzgerald restated a “buy” rating and set a $217.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, November 26th. BidaskClub downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 15th. Piper Jaffray Companies restated an “overweight” rating and set a $189.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 4th. Finally, BTIG Research set a $190.00 price objective on Sarepta Therapeutics and gave the company a “buy” rating in a research report on Monday, September 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twenty-three have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $169.19.

Shares of SRPT stock opened at $130.97 on Tuesday. Sarepta Therapeutics has a 1 year low of $50.68 and a 1 year high of $176.50. The company has a current ratio of 8.85, a quick ratio of 7.84 and a debt-to-equity ratio of 0.65. The company has a market cap of $8.65 billion, a price-to-earnings ratio of -79.86 and a beta of 1.84.

In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $140.50, for a total value of $936,713.50. Following the sale, the director now directly owns 126,534 shares in the company, valued at $17,778,027. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Douglas S. Ingram purchased 16,695 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, October 30th. The stock was acquired at an average price of $120.39 per share, for a total transaction of $2,009,911.05. Following the completion of the acquisition, the chief executive officer now owns 412,811 shares of the company’s stock, valued at approximately $49,698,316.29. The disclosure for this purchase can be found here. Corporate insiders own 7.90% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. First Quadrant L P CA purchased a new stake in shares of Sarepta Therapeutics in the third quarter worth approximately $130,000. Ffcm LLC purchased a new position in Sarepta Therapeutics during the 3rd quarter worth $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in Sarepta Therapeutics during the 2nd quarter worth $185,000. Keybank National Association OH purchased a new position in Sarepta Therapeutics during the 2nd quarter worth $206,000. Finally, Advisory Research Inc. purchased a new position in Sarepta Therapeutics during the 3rd quarter worth $214,000. Hedge funds and other institutional investors own 90.85% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

See Also: What impact do institutional investors have on markets?

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit